These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34236011)

  • 21. Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab.
    Miguel-Lillo B; Sánchez-Vidaurre S; Pérez Díaz L; Paravisini A
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01139. PubMed ID: 37920875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
    Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects.
    Hettema W; Wynne C; Lang B; Altendorfer M; Czeloth N; Lohmann R; Athalye S; Schliephake D
    Expert Opin Investig Drugs; 2017 Aug; 26(8):889-896. PubMed ID: 28651442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
    Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab.
    Schwabe C; Cole A; Espigares-Correa A; Beydon ME; Florez-Igual A; Queiruga-Parada J
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01070. PubMed ID: 36914963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
    Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A
    Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.
    Lee HA; Jang H; Jeong D; Kim Y; Fuhr R
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):269-279. PubMed ID: 35348111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
    Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
    BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
    Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
    Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
    Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
    Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
    Wynne C; Hamilton P; McLendon K; Stroissnig H; Smith M; Duijzings P; Ruffieux R; Otto H; Sattar A; Haliduola HN; Leutz S; Berti F
    Expert Opin Investig Drugs; 2023 May; 32(5):417-427. PubMed ID: 37212315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
    Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
    Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
    Eto T; Karasuyama Y; González V; Del Campo García A
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
    Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
    Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
    Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants.
    Yonemura T; Yazawa R; Haranaka M; Kawakami K; Takanuma M; Kanzo T; Stefanidis D; Arai Y
    BMC Pharmacol Toxicol; 2022 Jan; 23(1):6. PubMed ID: 34998419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.